T cell-based targeted immunotherapies for patients with multiple myeloma-Reference-Cited by-同舟云学术

T cell-based targeted immunotherapies for patients with multiple myeloma

Published:2014-09-19 Issue:8 Volume:136 Page:1751-1768
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Wang Lei¹,Jin Nan¹²,Schmitt Anita¹,Greiner Jochen³⁴,Malcherek Georg¹,Hundemer Michael¹,Mani Jiju¹,Hose Dirk¹,Raab Marc S¹,Ho Anthony D.¹,Chen Bao-an²,Goldschmidt Hartmut¹,Schmitt Michael¹

Affiliation:

1. Department of Internal Medicine V; University Clinic Heidelberg; University of Heidelberg; Germany

2. Department of Hematology; Zhongda Hospital, Southeast University; Nanjing China

3. Department of Internal Medicine III; Medical Clinic, University Clinic Ulm, University of Ulm; Ulm Germany

4. Diakonie-Hospital Stuttgart; Stuttgart Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference223 articles.

1. Multiple myeloma: evolving genetic events and host interactions;Kuehl;Nat Rev Cancer,2002

2. Centrosomal clustering-a novel therapeutic target for multiple myeloma;Raab;Blood,2009

3. Combining immunotherapy and targeted therapies in cancer treatment;Vanneman;Nat Rev Cancer,2012

4. Breakthrough of the year 2013. Cancer immunotherapy;Couzin-Frankel;Science,2013

5. Phase I/II study of elotuzumabplus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: updated phase ii results and phase i/ii long term safety;Facon;Haematologica,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen;Frontiers in Oncology;2020-09-02

2. MAGE genes: Prognostic indicators in AL amyloidosis patients;Journal of Cellular and Molecular Medicine;2019-06-20

3. Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system;Oncotarget;2017-01-19

4. Versican vs versikine: tolerance vs attack;Blood;2016-08-04

5. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies;Cellular and Molecular Life Sciences;2016-01-22